Biopharmaceuticals are an integral part of modern medicine and pharmacy. Both, the development and the biotechnological production of biopharmaceuticals are highly cost-intensive and require suitable expression systems. In this review we discuss established and emerging tools for reengineering the methylotrophic yeast Pichia pastoris for biopharmaceutical production. Recent advancements of this...

• P. tricornutum oligomannoside isomers are identical to the mammalian ones. synthesize a canonical Man 5 GlcNAc 2, substrate for GnT I. exhibits N -glycan profile that is suitable production of human biopharmaceuticals. Microalgae emerging systems recombinant proteins like monoclonal antibodies. In this context, characterization host cell N- glycosylation machinery and microalgae-made biopharm...

One of the main challenges for the production of biopharmaceuticals in plant-based systems is the modulation of plant-specific glycosylation patterns towards a humanized form. Posttranslational modifications in plants are similar to those in humans, but several differences affect product quality and efficacy and can also cause immune responses in patients. In the moss Physcomitrella patens high...

The broaden application of adoptive T-cell transfer has been constrained by the technical abilities to isolate and expand antigen-specific T cells potent to selectively kill tumor cells. With the recent progress in the design and manufacturing of cellular products, T cells used in the treatment of malignant diseases may be regarded as anticancer biopharmaceuticals. Genetical manipulation of T c...

Biopharmaceuticals are often produced by recombinant E. coli or mammalian cell lines. This is usually achieved by the introduction of a gene or cDNA coding for the protein of interest into a well-characterized strain of producer cells. Naturally, each recombinant production system has its own unique advantages and disadvantages. This paper examines the current practices, developments, and futur...

The preclinical development of biopharmaceuticals or biotechnology-derived pharmaceuticals such as monoclonal antibodies, recombinant proteins, growth factors, etc. does not follow the “standard” rule as opposed to small molecules or new chemical entities. In addition, the biopharmaceuticals, being in essence large molecules, are susceptible to be targeted by the immune system eliciting an immu...

The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of therapeutic proteins in formulation, or modifying pharmacokinetics in the body. Toward these obj...